search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
REGIONS EUROPE


Connectingbusiness with science


VCIIP IN LITHUANIA’S CAPITAL HAS CREATED A HOME FOR START-UPS AND MATURE COMPANIES IN THE LIFE SCIENCES, ALEX IRWIN-HUNT REPORTS


between business and science. Set across 24 hectares in an area located 30 minutes’ drive from the Old Town of Lithuania’s capital, VCIIP has devel- oped an ecosystemfor the formation


T


and growth of innovation-focused businesses. “We have practically everything,” says


Gediminas Pauliukevičius, the CEO of Northtown Vilnius, the operator of the indus- trial park (see interview on page 80). “[VCIIP is] a territory with fully developed infrastructure and communications, surrounded by pine for- ests, not far fromthe centre of Vilnius.” Since beginning operations in August 2018,


some 12 companies have either settled or are beginning to set up at VCIIP, covering areas ranging from laser and photovoltaic technol- ogy to medicine and biopharmaceuticals.


R&Dfocus In the case of Droplet Genomics, a start-up that develops and commercialises droplet microfluidics technology-based solutions for research applications, the environment at VCIIP is well suited for its research and devel- opment (R&D). “The VCIIPmanagement teamis highly ori-


ented to life sciences sector growth and has put significant effort into accommodating our requirements and helping us grow,” says Juozas Nainys, the CEO of Droplet Genomics, which raised a seed funding round of €1m in January 2021. By the end of 2022, a specialised


4000-square metre life sciences incubator will be built at VCIIP in collaboration with the Vilnius University Life Sciences Center, offer- ing laboratory facilities optimised for work with microorganisms, viruses and bacteria. The incubator will work alongside the existing digital innovation hub at the park, providing business advice and other services.


VCIIP ISAFUTURE CENTRE OF ACTIVITY FOR THE BIOTECHNOLOGY SECTOR


April/May 2021 www.fDiIntelligence.com


he Vilnius City Innovation Industrial Park (VCIIP) is refin- ing its recipe for collaboration


Mentorship and collaboration Povilas Kavaliauskas, co-founder of the Institute of Infectious Diseases and Pathogenic Microbiology, which is set to establish itself at VCIIP, finds the environment ideal for younger start-ups. “Even though there are several incubators


across the region, VCIIP provided a good resource, wet lab space and various mentor- ship and support programmes that are needed for young companies to navigate this often complex field,” he says. Petras Sabalys, CEO of biotech start-up


Sanobiotec, agrees. “[VCIIP] is a future centre of activity for the


biotechnology sector. The cluster of various companies creates a space for co-operation and collaboration, and inspired us to look for new approaches and methods,” he says. Sanobiotec, which is developing cannabi-


noid applications for both the wellness and pharmaceutical industries, has active com- mercial activities in 16 countries and has recently begun a Series A funding round. Mr Sabalys says the financing will be used


“to monetise the company’s extensive product portfolio in the key markets, further validate its products, expand the R&D operations and increase the production capacity”.


Covid-19 developments Some companies joining VCIIP have developed solutions in response to the pandemic. Imunodiagnostika, a start-up founded in 2013 that develops new systems for in-vitro diagnos- tics of allergies, created Lithuania’s first Covid-19 antibody test. Imunodiagnostika director Gintautus


Gylys says the company is preparing to scale manufacturing of its Covid-19 diagnostic test from the lab to large-scale production. The company plans to set up a factory and labora- tory to develop new products at VCIIP by 2022, a move which Mr Gylys sees as the next step in their development. “This will help to grow the company’s sci-


entific and innovative potential in the future,” he says. As the Lithuanian government proceeds


with its strategy to increase life sciences’ con- tribution to gross domestic product from 2% to 5% by 2030, VCIIP is hoping to attract more companies to create a value chain from R&D all the way to production.■


81


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96